Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 16Uterine Cervical Neoplasms 5Stomach Neoplasms 5Lung Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Hepatocellular 5Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Prostatic Neoplasms 4Ovarian Neoplasms 4Oropharyngeal Neoplasms 4Multiple Myeloma 4Esophageal Neoplasms 4Cholangiocarcinoma 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Neuroendocrine Tumors 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Anus Neoplasms 3Testicular Neoplasms 2Solid Tumor 2Pheochromocytoma 2Paraganglioma 2Pancreatic Neoplasms 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Leukemia, Myeloid, Acute 2Laryngeal Neoplasms 2

Interventions

Trastuzumab 14pertuzumab 10Docetaxel 7tucatinib 4pyrotinib 4Paclitaxel 4Capecitabine 4Carboplatin 2Ado-Trastuzumab Emtansine 2trastuzumab deruxtecan 1pegfilgrastim 1neratinib 1exemestane 1dalpiciclib 1atezolizumab 1Neoadjuvant Therapy 1Leuprolide 1Isovaleryl-CoA Dehydrogenase 1Injections 1Goserelin 1Genetic Testing 1Fulvestrant 1Fluorodeoxyglucose F18 1Blood Specimen Collection 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × Fluorodeoxyglucose F18 × 1 year × Clear all
NCT04273555 2026-02-06

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

University of Alabama at Birmingham

Phase 1/2 Withdrawn
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡